Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors

Published:2018-01-10 Issue:4 Volume:7 Page:e1417721
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Chen Chang-Long¹²,Pan Qiu-Zhong¹²,Weng De-Sheng¹²,Xie Chuan-Miao³,Zhao Jing-Jing¹²,Chen Min-Shan²⁴,Peng Rui-Qing¹,Li Dan-Dan¹,Wang Ying⁵,Tang Yan¹²,Wang Qi-Jing¹,Zhang Zhi-Ling⁶,Zhang Xiao-Fei¹²,Jiang Li-Juan⁶,Zhou Zi-Qi¹²,Zhu Qian¹²,He Jia¹,Liu Yuan¹²,Zhou Fang-Jian²⁶,Xia Jian-Chuan¹²

Affiliation:

1. Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China

2. Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China

3. Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China

4. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

5. Department of Immunization Program, Haizhu District Center for Disease Control and Prevention, Guangzhou, China

6. Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China

Funder

National Natural Science Foundation for Young Scholar of China

Guangdong Province Science and Technology Plan Project

National Natural Science Foundation of China (NSFC)

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1417721

Reference41 articles.

1. Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer

2. Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

3. Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma

4. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma;Clinical and Experimental Medicine;2024-08-28

2. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment;International Journal of Molecular Sciences;2024-05-17

3. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer;Molecular Cancer;2024-04-24

4. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial;Signal Transduction and Targeted Therapy;2024-04-03

5. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials;Journal of Leukocyte Biology;2024-02-19